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ABSTRACT: Resistance to treatment of different microorganisms 
has been considered a major concern in the public health and 
medical fields. Pharmacological, microbiological, immunological 
approaches and the search for therapeutic alternatives have gained 
prominence in this area in order to understand the theme. In this 
context, the objective was to compile information correlating with 
alternative therapies with the problem of bacterial diseases in view 
of the multidrug resistance developed by antibiotic superbugs, 
since they represent the main treatment used in patients with 
these comorbidities. The electronic bases used as facilitators of 
the theme included Scielo, PubMed, MEDLINE and LILACS, 
period 2010-2019. From the active approaches, it is observed that 
the expansion of the therapeutic collection and prolongation of 
treatment to all periods of the natural process of bacterial diseases, 
avoiding the imminent seclusion regarding the offer of treatments 
to the most distinct cases of resistance, is considered a differential 
aspect. Still, aiming at solving this impasse, seeking effective 
therapeutic alternatives in the treatment of the most varied cases 
of bacterial diseases, and the possibility of its execution, either 
exclusively or mainly complementary to the use of antibiotics. 
Multiple intervention possibilities have been considered to include 
haemofiltration devices, quorum detection inhibitors, advanced 
immunotherapies, bacteriophage use, alternative efforts to limit 
virulence, integrative medicine measures such as homeopathy 
and herbal medicine. After the analysis, it was concluded that 
due to its efficacy and selective mechanism of action among 
the therapeutic alternatives found, the most promising was the 
application of bacteriophages.
Keywords: Bacteriophages; Drug resistance, Bacterial infections; 
Complementary therapies.
RESUMO: Resistências para o tratamento a diferentes 
microrganismos têm sido considerado uma grande preocupação em 
ordem de saúde pública e área médica. Enfoques farmacológicos, 
microbiológicos, imunológicos e busca de alternativas 
terapêuticas têm ganhado destaque nesta área a fim de 
compreender a temática.  Neste contexto, objetivou-se compilar 
informações correlacionando-se com as terapias alternativas com 
a problemática das doenças bacterianas frente a multirresistência 
desenvolvida pelas superbactérias aos antibióticos, posto que 
representam o principal tratamento empregado em pacientes 
acometidos por essas comorbidades. As bases eletrônicas 
utilizadas como facilitadores da temática incluíram SciELO, 
PubMed, MEDLINE e LILACS, período 2010-2019. A partir 
das abordagens ativas, observa-se que ampliação do acervo 
terapêutico e prolongamento do tratamento a todos os períodos 
do processo natural de doenças bacterianas, evitando a iminente 
reclusão quanto a oferta de tratamentos aos mais distintos casos 
de resistência, é considerado um aspecto diferencial. Ainda, 
objetivando solucionar esse impasse, buscar de alternativas 
terapêuticas efetivas no tratamento dos mais variados casos de 
doenças bacterianas, e a possibilidade de sua execução, seja 
de modo exclusivo ou principalmente complementar ao uso de 
antibióticos. Múltiplas possibilidades de intervenção tem sido 
considerados a incluir dispositivos de hemofiltração, inibidores 
de detecção de quórum, imunoterapias avançadas, uso de 
bacteriófagos, esforços alternativos para limitar a virulência, 
medidas da medicina integrativa como a homeopatia e a 
fitoterapia. Após as análises, concluiu-se que devido a sua eficácia 
e mecanismo de ação seletivo entre as alternativas terapêuticas 
encontradas, a que se mostrou mais promissora foi a aplicação 
de bacteriófagos. 
Descritores: Bacteriófagos; Resistência a medicamentos; 
Infecções bacterianas; Terapias complementares.
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INTRODUCTION
Twentieth century medicine had an essential advance in the treatment of infectious diseases, 
antibiotic therapy. In 1940, Alexander Fleming discovered 
the first biological antibiotic, penicillin, and along with it, 
he was already aware that resistance to this drug would be 
added to its use, so it must be accompanied. Contributing 
to this thought, after a year of this discovery, Barber proved 
in an experiment the ability of bacteria to resist penicillin 
from penicillinases that degrade such an antibiotic1.
Resistance mechanism transmission is now known 
to occur intrinsically or acquired through varying function 
gains through the production of new penicillin-binding 
proteins, enzymatic drug-altering mechanisms, altered 
therapeutic targets, efflux pumps. increased and changes 
in membrane permeability. Even though they are aware 
of their disadvantages, the Western world has adopted the 
widespread and indiscriminate use of antibiotics, which 
today corroborated that resistance to these drugs is one of 
the most serious health problems, not only because of the 
selective pressure exerted by their intensive use, as well 
as the process of developing new antimicrobial drugs1,2.
Explaining the practical reality of this problem, it 
is exemplified that in the United States (USA) annually, at 
least 2 million people are infected with resistant bacteria, 
and antimicrobial resistance is costly and has an estimated 
impact of 20 billion of dollars annually in that country. 
In Europe, the total annual cost associated with bacterial 
resistance is over € 1500 million, a figure that may be 
underestimated. In addition, an estimate made by the World 
Health Organization is that by 2050 superbugs can account 
for about 10 million deaths per year and will cost the global 
economy approximately $ 84 trillion1,3,4.
Aware of these problems, Brazil has been at the 
forefront since 2013, generating Patient Safety and Quality 
in Health Services (GVIMS) Newsletters. The first report 
from the National Resistance Monitoring Network included 
data from 908 hospitals in 26 of the 27 Brazilian federative 
units, with data on the resistance phenotypes of 19,009 
microorganisms responsible for causing IPCSL (Primary 
Laboratory Bloodstream Infection) in Brazilian ICUs. From 
this information, it was confirmed that microbial resistance 
is a public health problem in all regions of the country. 
Figure 1 illustrates the percentage profile of resistant 
bacteria in ICU infected patients in the state of São Paulo5.
Figure 1: Percentage of resistant bacteria in infected patients in the ICUs of São Paulo State (Source: Epidemiological Surveillance 
Center / SP)5
If interventionist measures are not taken for the 
exposed reality, the therapeutic failure of antibiotics will 
culminate in increased days of hospitalization, morbidity, 
persistence of the infectious process with consequences 
on nosocomial infection, mortality and associated costs. 
This problem may become even more serious that a 
common infection becomes highly complex, becoming 
intractable, and interventional procedures, from surgery, 
chemotherapy, organ transplantation or neonatal care, are 
at risk of becoming impracticable1.
In addition to that, due to the low profitability and 
growing lack of interest in the laborious production of new 
antibacterials by the pharmaceutical industry, the choice 
of new therapeutic methods is extremely important due to 
their economic repercussions6.
Aware of the situation presented, and intending to 
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contribute to the growing demand for new interventional 
measures in bacterial diseases, alternative ways to the use 
of antibiotics have gained power in the research market. 
Therefore, it would be necessary to seek solutions that 
would combat them as a whole, both in their incidence, 
through the introduction of preventive measures, and 
investing in different therapeutic methods, in cases that 
could not be prevented7.
METHODS
In this study, which follows the bibliographic review 
model, the objectives are achieved based on information 
collected in scientific articles, research sites such as 
CAPES, SciELO, Pubmed, CNPq and FAPESP platforms. 
It compiled the use of an updated theoretical framework 
from 2010 to 2019. Aiming to further investigate the 
sources of information, it was necessary to systematically 
divide the scientific articles from a flowchart identified 
in Figure 2, allowing for a prospective progress between 
the introduction. The bibliographical selection and the 
compilation of articles, expanding the production of the 
discussion and the conclusion. Descriptors used for the 
conduct of this study included: Bacteriophage, bacterial 
multidrug resistance, bacterial diseases, alternative 
therapies.
Figure 2: Flowchart elaborated from the methodology used for data collection of this study
DEVELOPMENT
To facilitate the understanding of the data obtained, 
it is possible to observe in Image 3 the elaboration of a 
flowchart where we identify the search for therapeutic 
alternatives to bacterial diseases that can cause even 
multidrug resistance. Thus, the pathological conditions 
involving bacterial diseases encouraged the incessant 
investigation for therapeutic measures that could be applied 
to bacterial diseases. We may consider that the search 
ceased in 1940 with Fleming’s discovery of antibiotics, 
but at the same time the perception that along with these 
drugs, superbugs could develop into an even worse 
reality, multidrug resistance. Surrounded by this reality, 
it is possible to question whether Fleming’s discovery 
culminated in the return to the search for other alternatives, 
in a scenario where bacterial diseases are still present 
and multidrug resistance gains even more frightening 
proportions than the initial one.
 Motivated by the exploration of strategies for 
this topic, we found several possibilities for alternative 
interventions including hemofiltration devices, quorum 
detection inhibitors, advanced immunotherapies, alternative 
efforts to limit virulence, integrative medicine measures 
such as homeopathy and herbal medicine, but mainly 
the most promising one, the use of bacteriophages8. 
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Figure 3- Flowchart containing alternative therapeutic strategies for bacterial diseases that can cause multidrug resistance
Therapeutic alternatives
Hemofiltration devices act as extracorporeal filters, 
aiming to allow the innate and adaptive host immune 
system to remove agents and their possible panresistent 
residues to microbial agents. Some of these devices 
simulate the action of the human spleen and are studied 
for the possible treatment of sepsis. They operate through 
magnetism, causing the opsonization of one or several types 
of microorganisms, sculpting a microfluid arrangement 
similar to the spleen and thus allowing the elimination of 
pathogens8,9.
As bacterial action in biofilms of chemical signal 
release and gene expression is subject to quorum detection, 
which allow the coordination of a collective behavior of 
bacteria, which act similar to multicellular organisms. 
Inhibiting agents of this detection represent a practical 
clinical benefit against multiresistant pathogens, that 
bacteria use a type of intercellular communication to alert 
pathogens about their collective bacterial concentration, 
which when elevated can change their transcription profiles 
to an invasive phenotype. Thus, quorum detection block 
has the ability to improve results in experimental models of 
systemic infection, representing another promising method 
for the treatment of bacterial diseases8,10,11,12.
Another therapeutic measure is advanced 
immunotherapies, which although it is not a new approach, 
can still be innovated by generating high affinity polyclonal 
and monoclonal human antibodies against a range of 
molecular targets is making them more attractive. Proof of 
this is that adjuvant active immunization with multiepitope 
vaccines, as well as monoclonal and polyclonal antibodies, 
as passive therapies against bacterial pathogens, is being 
developed, aiming to boost the host’s cellular and humoral 
adaptive immunities, thus representing the possibility 
of use for prophylaxis or for pre- or post-exposure 
treatment. Several adjuvants are under investigation, 
including interleukin-7, macrophage and granulocyte 
colony stimulating factor, apoptosis inducing antibody, it 
is expected that such immunological adjuvants may benefit 
patients with sepsis-induced immunosuppression8,13.
Corroborating the other therapeutic alternatives 
are virulence limiting mechanisms, which are inhibitors 
of modified liposome-based cytotoxins, which capture 
a variety of bacterial toxins with cell membrane lysis 
capability. These liposomes serve as cell membrane 
chemoattractants to absorb cytotoxins, protecting 
human cells from injury. This non-antibiotic defense 
mechanism experimentally protects and could complement 
antimicrobial agents in the treatment of exotoxin-producing 
bacterial infections8.
Integrative Medicine
In Integrative Medicine homeopathy is formulated 
considering the Hippocratic concept, which is based on 
the idea that the disease is produced by the similar and 
by the similar the patient returns to health. From this, this 
practice is articulated by the association between medicine 
and pharmaceutical, which aims for minimum doses of 
medicine to stimulate the organic reaction to cure and thus 
prevent the aggravation of symptoms. This practice is based 
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on the philosophical character that the manifestation of a 
disease present in the patient will also be present in a certain 
substance, so when administered to a healthy individual, 
it will present the patient’s symptoms. Using this specific 
substance the homeopathic clinician will transform it into 
the necessary medicine by the dynamization method, which 
allows to reduce the toxic effects of the original substance 
and increase its healing potential. It is concluded from 
this that the drug has the power to make the body react 
immunologically, fighting these symptoms, seeking cure14.
A study by Furuta et al.15 involving samples of 
pediatric patients showed that children had a diagnosis of 
recurrent tonsillitis, which were divided into two double-
blind groups, where a group of 20 patients would receive 
homeopathic medicine and another group of 20 patients 
would receive a placebo. Both groups underwent through 
a daily treatment for 4 months. At the end of the study, 
among the group treated with homeopathic medicine, 22% 
of patients had acute tonsillitis and 78% did not, while in 
the placebo group 67% of patients had acute tonsillitis and 
33% did not. This statistic demonstrates a greater efficacy 
favorable to the use of homeopathic treatment15.
In addition to that, the use of herbal medicine, 
effective in primary health care, is embodied by the use 
of medicinal plants in their pharmaceutical form, with 
the purpose of preventing or curing pathologies. For 
developing countries, where the rate of use of herbal 
medicines has about 80% of adherents, they need to have 
greater cultural acceptability and accessibility to treatment, 
to achieve high compatibility with the human body and 
minimize its side effects. Therefore, when compounds 
derived from medicinal plants are used to inhibit and 
destroy pathogens, they have infamous host cell toxicity 
and are therefore excellent for a new antimicrobial16.
It is necessary to understand that this alternative is 
one of the main resources of Alternative Medicine and that 
it has been used for a long time by the Brazilian population. 
Coupled with this, it is important to recognize its notoriety 
among patients who hardly have access to primary health 
care and also to the allopathic remedy due to its high cost17.
Nascimento-Junior et al.17 show that during the 
execution of a cross-sectional study involving 96 higher 
education professionals working in the Family Health 
Strategy Program, they are not able to disseminate 
information about alternative use as a treatment choice, 
regardless of the disease. In this study, we analyzed the 
perception of importance, use and indications of Medicinal 
and Herbal Plants. This reality culminates in the elimination 
of one more possibility that could be offered to patients 
looking for more natural and less costly treatment solutions, 
not only harming the service that could be better17.
The result was conflicting and it can be noted that 
a large part is not prepared to pass on information on the 
use of medicinal plants or prescribe herbal medicines to 
the population, and this ends up causing great harm to 
the service, because this Complementary and Alternative 
Medicine is a good option and generally have a lower cost18.
At the community level, urinary tract infection is 
the most common of infections, being more prevalent in 
women because of the ease that anal microorganisms have 
to reach the female urethra and result in this disease. An 
effective treatment method for this condition is to increase 
diuresis by administering diuretic substances, favoring an 
effective cleansing of crystallization nuclei and bacteria that 
may be in the urinary tract. In this regard, the use of herbal 
medicine through plants that have a promising character in 
increasing renal water excretion is relevant1,19.
Bacteriophages
Analyzing the lytic bacteriophages, their means of 
replication is through the insertion of their genetic material, 
which will lead to bacterial cellular machinery replicating 
the transmitted viral information. This occurs much faster 
than the bacteria itself. Having completed the process 
of synthesis and assembly of new phages, these will be 
released by bacterial cell lysis and will have the ability to 
initiate a new replication cycle. For this reason, natural 
control antimicrobial agents are considered1.
There is a great need for safe and effective 
antimicrobial treatment options, as antibiotics have 
limitations, such as poor penetration into bacterial 
biofilms and the growing emergence of resistant bacterial 
strains. As noted, the use of strictly lytic bacteriophages 
has played an active role in this research and has been 
suggested as an alternative or complement to conventional 
chemical antibiotics, allowing them to act as natural 
predators directly on bacteria. Antibiotic therapy with 
phages has great advantages compared to conventional 
chemical antibiotics, among these advantages is the great 
specificity that they have when replicating directly at the 
site of infection, being abundantly available where they are 
most needed and their dependence on the host bacteria to 
multiply, makes it exist only until it is exterminated20,21,22.
Phage therapies can be differentiated in several 
ways, including their place of administration (topical, oral, 
systemic or even directly onto body tissues). In addition, 
phage delivery to intracellular pathogens, the most common 
being the administration of free phage or bacteria already 
infected with phage, is another mode of differentiation. 
They can also be genetically altered to deliver non-phage 
genes encoding specific antibacterial agents. In order 
to ascertain the effectiveness of bacteriophages in the 
bloodstream, it is possible to develop a phage cocktail with 
the host-specific phage formulation range by mixing two or 
more bacteriophages called “phage cocktails”22.
Comparing the therapeutic alternatives shows that 
the most promising was the bacteriophages, having the 
advantage of their long developmental period, similar to the 
antibiotic, but with lower cost and greater efficacy. In order 
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to demonstrate its effectiveness, Schooley’s23 data illustrate 
an intravenous infusion of 1.8E + 04 bacteriophages in 
a patient with a bacterial disease who was resistant to 
antibiotics. It is possible to observe that within 360 minutes 
after its use, the bacteriophage concentration reached level 
0, because its survival viability in the human organism is 
restricted to its reproduction within the bacteria23.
Thus, by acting on specific receptors of the disease-
causing microorganism, preventing their replication and 
survival in the host cell, both are exterminated. To ensure 
that this occurs in situ, the modification of the phage for its 
immunogenicity or even the selection of long-circulating 
phages has the ability to decrease its clearance by cells 
of the reticuloendothelial system (RES), corroborating a 
better action6,23.
In the f ields of  infect ious diseases and 
gastroenterology, Sabino et al.24 show that phage therapy 
is a promising therapeutic tool against pathogenic bacteria. 
Randomized, placebo-controlled studies with phage 
therapy for gastroenterological diseases are ongoing24.
Bacteria may develop resistance to antibiotics. 
Even without changing genetically, bacteria can also 
exhibit tolerance to antibiotic treatments. Many antibiotics 
are also acting broadly as they can result in excessive 
modifications of the body’s microbiomes. Particularly for 
antibiotics of last resort or in the treatment of extremely 
ill patients, antibiotics may also exhibit excessive toxicity. 
Antibiotics, however, remain the standard treatment for 
bacterial infections, and rightly so, because of their long 
record of antibacterial efficacy and infrequent side effects. 
Antibiotics do not successfully cure all treated bacterial 
infections, however, thus providing a utility for alternative 
antibacterial approaches. One such approach is the use of 
bacteriophages, bacterial viruses25.
This nearly 100-year-old anti-bacterial infection 
technology can be effective against antibiotic resistant or 
tolerant bacteria, including bacterial biofilms and persistent 
cells. Ideally, phages could be used in combination with 
standard antibiotics while maintaining their antibacterial 
pharmacodynamic activity, although antibiotics interfere 
with aspects of bacterial metabolism that are also required 
for the full activity of phage infection. Abedon (2019) 
through a literature review identified preclinical combined 
treatments with phages and antibiotics, with emphasis 
on antibiotic-susceptible bacterial targets. Evidence of 
antibiotic interference on phage infection activity, together 
with its inverse, suggests the antibacterial functioning of 
phages despite the presence of antibiotics25.
The prospects for endolysins are enhanced by 
the ability to design them; New endolysins can be 
developed with optimized stability, specificity and lytic 
function. Thus the growth of endolysin engineering and 
application requires a comprehensive understanding of 
the relationship between the biochemical, biophysical and 
bacteriolitic properties of enzymes. Love et al.26 report that 
bacteriophage endolysins have the potential to be a long-
term antibacterial substitute for antibiotics with exogenous 
application of endolysins in some bacteria resulting in 
rapid cell lysis.
The high success rate and safety of phage therapy 
compared to antibiotics is partly due to its specificity for 
selected bacteria and the ability to infect only one species, 
serotype or strain. This mechanism does not cause the 
destruction of commensal bacterial flora. Phages are 
currently being used successfully in humans and animals 
in therapies directed at slow cure infections. They have also 
found application in the US to eliminate surface pathogens 
from animal and plant foods. At a time of increasing 
antibiotic resistance in bacteria and the resulting restrictions 
on antibiotic use, bacteriophages may provide an alternative 
means of eliminating pathogens27.
The effectiveness of phytotherapy and homeopathy 
is proven by numerous studies, showing to be superior to 
the isolated or combined use of the antibiotic. However, the 
expansion of its use requires the rupture of socio-cultural 
paradigms, such as the disbelief of its effectiveness by 
the population that prevents the full adhesion of these 
alternatives. For this, it is possible to follow its prodigious 
application in the Eastern World and make it a model to 
be followed in order to consolidate these practices in the 
Brazilian reality.
With regard to the other methods covered, such 
as use of hemofiltration devices, quorum detection 
inhibitors, virulence limiting devices and use of advanced 
immunotherapies, these methods still require a lot of 
research time and high investments, delaying their access 
to public. Moreover, they represent highly complex 
methods, which today would contribute to the restricted 
application of these alternatives, generating a population 
fractionation for their use, so it is desired that plausible 
ways to disseminate them to a larger number of people 
are studied.
CONCLUSION
Compiling the full picture of bacterial diseases, the 
solution to the initial project inquiry would include the 
pre-pathogenic period to prevent the exponential incidence 
of multidrug resistance. To this end, it is recommended 
that basic measures be taken at the primary prevention 
level in order to eradicate the sometimes unnecessary and 
excessive prescription of antibiotics that is made in the 
health area, and their banalization by professionals, which 
often allow them to spread. the belief that the use of these 
drugs can be rampant or even devalue the consequences 
they can cause. In addition, incorrect administration by 
patients, many of whom are unoriented and unaware of its 
complexity, discontinue treatment before its completion, 
consume alcohol concomitantly with the use of the drug 
and use prescription drugs when unfinished.
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Considering the cases in which multidrug 
resistance already exists, the application of alternative 
therapeutic measures to the use of antibiotics represents 
the consolidation of equity in the treatment of patients. 
Since there would be expansion in the collection of 
possible measures to be offered to each person according 
to their integral needs and considering the pathogenic 
phase in which they were inserted, and not according to a 
generic context. And despite the obstacles encountered in 
increasing resistance, bacteriophages along with the various 
other therapeutic alternatives play a major role in trying to 
reverse and eradicate the millions of multidrug resistance 
cases already in the world and generate a scenario of hope 
for their effectiveness. and its applicability.
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